年龄相关性黄斑变性基因型检测方法的开发:EYE-RISK联盟研究
EYE-RISK联盟开展病例对照研究,纳入5个欧洲队列4740人,利用单分子分子倒置探针靶向捕获和二代测序检测87个SNP及10个AMD相关基因和3个遗传性黄斑营养不良基因的编码及剪接区。研究成功构建了针对常见和罕见AMD风险变异的基因型检测方法,可计算遗传风险评分并鉴别模拟AMD的遗传性黄斑营养不良。
要点
- 该检测平台与其它基因分型平台对69个成功分型的SNP一致性>96%,罕见变异一致性>99%。
- 晚期AMD患者遗传风险评分显著高于早期/中期AMD患者(P<0.001)及无AMD个体(P<0.001)。
- 晚期AMD患者中CFH(OR=2.88; P=0.006)、CFI(OR=4.45; P=0.005)、C3(OR=6.56; P=0.0003)致病性变异比例更高。
核心结论
- 研究报道了一种可检测AMD常见和罕见遗传变异的基因型检测方法,能识别晚期AMD中高危遗传风险个体并鉴别模拟AMD的黄斑营养不良。
研究设计与样本
- 病例对照研究,纳入来自5个欧洲队列的4740名个体。
- 采用单分子分子倒置探针靶向选择和二代测序,检测87个SNP、10个AMD相关基因及3个遗传性黄斑营养不良基因的编码和剪接区。
- 基于52个AMD相关变异的效果量和基因型计算常见AMD风险变异的遗传风险评分。
主要发现
- 平台与其它基因分型平台对69个成功分型的SNP一致性>96%,对罕见变异一致性>99%。
- 晚期AMD患者遗传风险评分高于早期/中期AMD患者(P<0.001)和无AMD个体(P<0.001)。
- 晚期AMD患者中CFH(OR=2.88; P=0.006)、CFI(OR=4.45; P=0.005)、C3(OR=6.56; P=0.0003)致病性变异比例高于对照。
- 在9名患者中鉴定出PRPH2、ABCA4和CTNNA1基因致病性变异,使这些患者被重新分类为遗传性黄斑营养不良。
关键数值与推荐
- 基于52个AMD相关变异的效果量和基因型计算遗传风险评分。
- 晚期AMD患者中CFH、CFI、C3罕见高风险变异比例显著高于对照(OR分别为2.88、4.45、6.56)。
临床怎么用
- 该检测可识别晚期AMD中高危遗传风险个体,并辅助鉴别模拟AMD的遗传性黄斑营养不良。
- 研究支持对CFH、CFI和C3基因进行测序,因其携带罕见高风险变异,携带者可能适合目前正在开发的新疗法。
局限性
- 研究基于5个欧洲队列的病例对照设计,样本来源有限。
- 罕见变异频率比较采用逻辑回归分析,未报告其他潜在混杂因素的控制情况。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To develop a genotype assay to assess associations with common and rare age-related macular degeneration (AMD) risk variants, to calculate an overall genetic risk score (GRS), and to identify potential misdiagnoses with inherited macular dystrophies that mimic AMD. DESIGN: Case-control study. PARTICIPANTS: Individuals (n = 4740) from 5 European cohorts. METHODS: We designed single-molecule molecular inversion probes for target selection and used next generation sequencing to sequence 87 single nucleotide polymorphisms (SNPs), coding and splice-site regions of 10 AMD-(related) genes (ARMS2, C3, C9, CD46, CFB, CFH, CFI, HTRA1, TIMP3, and SLC16A8), and 3 genes that cause inherited macular dystrophies (ABCA4, CTNNA1, and PRPH2). Genetic risk scores for common AMD risk variants were calculated based on effect size and genotype of 52 AMD-associated variants. Frequency of rare variants was compared between late AMD patients and control individuals with logistic regression analysis. MAIN OUTCOME MEASURES: Genetic risk score, association of genetic variants with AMD, and genotype-phenotype correlations. RESULTS: We observed high concordance rates between our platform and other genotyping platforms for the 69 successfully genotyped SNPs (>96%) and for the rare variants (>99%). We observed a higher GRS for patients with late AMD compared with patients with early/intermediate AMD (P < 0.001) and individuals without AMD (P < 0.001). A higher proportion of pathogenic variants in the CFH (odds ratio [OR] = 2.88; P = 0.006), CFI (OR = 4.45; P = 0.005), and C3 (OR = 6.56; P = 0.0003) genes was observed in late AMD patients compared with control individuals. In 9 patients, we identified pathogenic variants in the PRPH2, ABCA4, and CTNNA1 genes, which allowed reclassification of these patients as having inherited macular dystrophy. CONCLUSIONS: This study reports a genotype assay for common and rare AMD genetic variants, which can identify individuals at intermediate to high genetic risk of late AMD and enables differential diagnosis of AMD-mimicking dystrophies. Our study supports sequencing of CFH, CFI, and C3 genes because they harbor rare high-risk variants. Carriers of these variants could be amendable for new treatments for AMD that currently are under development.
引用
- de Breuk A, Acar IE, Kersten E, et al. Development of a Genotype Assay for Age-Related Macular Degeneration: The EYE-RISK Consortium. Ophthalmology. 2020. PMID: 32717343. doi:10.1016/j.ophtha.2020.07.037
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。